Connor, Clark & Lunn Investment Management (CC&L)
VIRX

Connor, Clark & Lunn Investment Management (CC&L)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-170
Closed -$87K – 672
2015
Q1 		$87K Buy
+170
New +$85.8K ﹤0.01% 538

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VIRX Position: Q2 2015 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2015, closing a stake of 170 shares — an estimated $87K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VIRX in Q1 2015 and held it in 1 quarter. The position peaked at $87K in Q1 2015. 80 funds tracked by Wall St. Rank hold VIRX as of Q2 2015.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 170 Viracta Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $87K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Viracta Therapeutics, Inc. Common Stock position peaked at $87K in Q1 2015.
  • 80 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2015, filed 14 Aug 2015.